Advisory Research’s Transmedics TMDX Stock Holding History

Advisory Research’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-45,216	Closed	-$3.57M	–	308
2023 Q4	$3.57M	Sell	45,216 -7,146	-14%	-$431K	0.55%	42
2023 Q3	$2.87M	Sell	52,362 -21,174	-29%	-$1.52M	0.4%	66
2023 Q2	$6.18M	Buy	73,536 +33,787	+85%	+$2.59M	0.79%	25
2023 Q1	$3.01M	Buy	39,749 +22,659	+133%	+$1.57M	0.49%	52
2022 Q4	$1.05M	Buy	17,090 +9,161	+116%	+$487K	0.1%	159
2022 Q3	$331K	Buy	+7,929	New	+$345K	0.03%	274

Other funds holding TMDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisory Research's TMDX Position: Q1 2024 in Review

Advisory Research sold out of Transmedics (TMDX) in Q1 2024, closing a stake of 45,216 shares — an estimated $3.57M sold.

Advisory Research first reported a position in TMDX in Q3 2022 and held it in 6 quarters. The position peaked at $6.18M in Q2 2023. 263 funds tracked by Wall St. Rank hold TMDX as of Q1 2024.

Advisory Research reported no remaining Transmedics position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 45,216 Transmedics shares in Q1 2024, an estimated $3.57M.
Advisory Research first reported a position in Transmedics in Q3 2022 and held it in 6 quarters.
Advisory Research's Transmedics position peaked at $6.18M in Q2 2023.
263 funds tracked by Wall St. Rank held Transmedics as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.